Evaluation of the Condition of Rheumatoid Arthritis After Treatment


To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients

Full Title of Study: “Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2016


  • Drug: The effectiveness of Xeljanz in rheumatoid arthritis patients

Arms, Groups and Cohorts

  • Experimental: The condition of rheumatoid arthritis

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline of clinical evaluation in rheumatoid arthritis
    • Time Frame: Every month
    • DAS28, SDAI, Blood testing, Plain radiograph, and Ultrasound will be performed.

Secondary Measures

  • Number of participants with adverse events
    • Time Frame: Every month

Participating in This Clinical Trial

Inclusion Criteria

  • Rheumatoid arthritis Exclusion Criteria:

  • Other connective tissue disease

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Shinshu University
  • Collaborator
    • Showa Inan General Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yukio Nakamura, Assistant Professor – Shinshu University
  • Overall Contact(s)
    • Yukio Nakamura, MD, PhD, yxn14@aol.jp

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.